New Oxygen-enhanced Imaging Technique Identifies Aggressive Prostate Cancer in Mice

New Oxygen-enhanced Imaging Technique Identifies Aggressive Prostate Cancer in Mice
A new imaging technique called oxygen enhanced optoacoustic tomography (OE-OT) may improve the ability to distinguish between aggressive and less-aggressive prostate cancer cases, identifying those patients who can undergo chemo and/or radiation therapy, according to researchers. The study, titled “Oxygen Enhanced Optoacoustic Tomography (OE-OT) Reveals Vascular Dynamics in Murine Models of Prostate Cancer,” was published in the journal Theranostics. Tumor cells grow much faster than normal cells and eventually need their own supply of blood. But the resulting blood vessels tend to have different properties between patients. A tumor may have good or poor quality blood vessels, both of which lead to very different tumor environments. Poor quality blood vessels contribute to a condition called hypoxia, which refers to low oxygen levels, and can lead to increased resistance to chemotherapy and radiotherapy. Therefore, the ability to noninvasively image the oxygen supply of tumors in prostate cancer can help improve diagnosis and aid with the staging of the disease by being able to identify the more aggressive, hypoxic tumors and the less aggressive, oxygen-reliant tumors. Currently, there are some approaches that can measure oxygen supply that have been investigated in cancer, such as special versions of magnetic resonance imaging (MRI) and positron emission tomography (PET). But while these methods hold promise, they have limitations. Therefore, there is a need for better imaging of oxygen supply. The new approach, called optoacoustic tomography (OT), currently in cl
Subscribe or to access all post and page content.

Tagged , , , .

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

2 comments

  1. Stephen B. Strum, MD, FACP says:

    For us clinicians treating prostate cancer there are many publications that are stimulating/tantalizing but their ability to be translated into patient care now or in the next few months is often just not there. I term this stimulation without gratification and perhaps we can come up with a new concept called Translational Coefficient (TC) that is an indicator of how likely something new will make it into the sphere of patient evaluation and/or treatment in the next 6 months (TC4), 1 year (TC3), 2 years (TC2), 3 or more years (TC1), or unlikely in the foreseeable future (TC0). A TC of 2-4 is worth keeping tabs on but lower levels are likely to disappear into the vapor of “could’ve beens”, and there are many of those.

    As a student of prostate cancer since 1983, and having treated many thousands of patients over the last almost 35 years, there are currently many technologies that are NOT making it into real time medicine. Even basic imaging studies to ascertain stage of prostate cancer are not being subjected to head-to-head studies to determine is one imaging study better than the other (e.g., 68Ga-PSMA PET/CT versus Tc99 bone imaging vs CT abdomen/pelvis vs NaF PET/CT). How in the world does a clinician chose when no direct comparison studies are reported?!

    Insofar as oxygen enhanced optoacoustic tomography (OE-OT), this sounds wonderful but how many years will go by before this is clinically available and after that will there be a study(ies) to show superiority over other testing? Is multi-parametric MRI (mp-MRI) that uses DCE (dynamic contrast enhancement) able to be a more accurate test if DCE is discarded and OE-OT used instead? Is there a mouse study of prostate cancer that shows this superiority of OE-OT right now? We need usable new developments and less so for those that take the life time of the clinician from concept to patient use.

  2. Leandro Simosa says:

    I did not know about this but I am glad there are new options for bph because I know that Living with bph is hard, it is so uncomfortable,one of my symptoms was frequent urination at nights, it was terrible, I even got worried because diabetes is running in my family (my uncle and my brother have diabetes), so it made me go to the doctor and after some checks he told me the real cause of this is my prostate, bph ( I thought it means I have cancer, so glad I was wrong). Anyways, He gave a diet based on foods that are good for the prostate such as fish (omega3), tomatoes and others, also he asked me to take a natural supplement that is named alpha rise, the combination of the supplement and the diet have helped me a lot. I hope my story can help someone

Leave a Comment

Your email address will not be published. Required fields are marked *